NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
ملاحظة
NVAX is finally climbing back up over 25% since April 1st. Call options for 5/19 are up over 100% adding into the trade now.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.